# A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

> **NCT01195974** · PHASE1 · TERMINATED · sponsor: **ViiV Healthcare** · enrollment: 13 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** YASMIN
- **DRUG:** GSK2248761
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01195974
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09-14
- **Primary completion:** 2011-02-09
- **Final completion:** 2011-02-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** In a Phase II study in HIV-infected patients there were a number of seizures, although exact causality could not be assessed phase 1 activity was terminated.
- **Last updated:** 2019-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01195974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01195974, "A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01195974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*